Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Selincro

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

nalmefene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
[Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence].
  • Y. Tadori
  • Nihon yakurigaku zasshi. Folia pharmacologica…
  • 2020
  • Corpus ID: 211726945
Nalmefene (Selincro®), an opioid receptor modulator, is approved in Japan, the European Union, and other countries for reducing… 
2016
2016
STREAM: Elucidating How Alcohol Use Disorders are Managed in UK General Practice Today.
AIMS To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
Nalmefene is effective at reducing alcohol seeking, treating alcohol‐cocaine interactions and reducing alcohol‐induced histone deacetylases gene expression in blood
The opioid antagonist nalmefene (selincro®) was approved for alcohol‐related disorders by the European Medicines Agency in 2013… 
2016
2016
Nalmefene and opioids: A contra-indication to remember
Introduction Nalmefene (NMF – SELINCRO®), a drug for alcohol withdrawal management (AWM), is both a partial agonist and an… 
Review
2015
Review
2015
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the… 
  • table 1
2015
2015
Severe opioid withdrawal syndrome after a single dose of nalmefene
Case 1 A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of… 
2015
2015
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of… 
Review
2014
Review
2014
Bad medicine: nalmefene in alcohol misuse
  • D. Spence
  • BMJ : British Medical Journal
  • 2014
  • Corpus ID: 38653312
Both Glasgow and medical school were hard drinking gigs. I enjoy alcohol and drink it for its psychoactive effect rather than for… 
2014
2014
Nalmefene: a guide to its use in alcohol dependence
The opioid system modulator nalmefene (Selincro®) is the first pharmacological therapy to be approved in the EU to reduce alcohol… 
Review
2013
Review
2013
Nalmefene: A Review of Its Use in the Treatment of Alcohol Dependence
The opioid system modulator nalmefene (Selincro®) is approved in the EU for as-needed use to reduce alcohol consumption in… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE